Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future

Main Article Content

Chancellor E. Donald (1*), Luis E. Raez (2), Edgardo S. Santos (3)

1 Hematology/Medical Oncology, Tulane University Health Sciences Center, Tulane Cancer Center, New Orleans, United States.
2 Hematology/Oncology Division, Thoracic Oncology Group, Sylvester Comprehensive Cancer Center, University of Miami Leonard M. Miller School of Medicine, Miami, United States.
3 Hematology/Oncology Division, Thoracic Oncology Group, Sylvester Comprehensive Cancer Center, University of Miami Leonard M. Miller School of Medicine, Miami, United States.
(*) Corresponding Author:
Chancellor E. Donald
cdonald@tulane.edu

Abstract

The understanding of the epidermal growth factor pathway in terms of intracellular signaling and its role in proliferation and cell survival has impacted the therapeutic management of many solid tumor malignancies in which this pathway has been dysregulated. Once the receptor is targeted at its cellular membrane level or tyrosine kinase domain, its blockage induces downregulation of oncogenic and tumorigenesis mechanisms which were in place, and thus inhibits proliferation and induces apoptosis of the malignant cell. Nowadays, we have several monoclonal antibodies as well as small molecules which target the receptor of epidermal growth factor. Although several receptors have been described within the human epidermal receptor family, our discussion will be focused on the impact of human epidermal receptor-1 as a therapeutic option for locally advanced squamous cell carcinoma of the head and neck.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

How to Cite
Donald, C. E., Raez, L. E., & Santos, E. S. (2011). Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future. Oncology Reviews, 3(3), 137-148. https://doi.org/10.4081/oncol.2009.137